Evidence map›Paper›PMID 35217831›Full record

ArticleProstate cancer and prostatic diseases2023

Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer.

Jacob E Tallman, Christopher J D Wallis, Li-Ching Huang, Zhiguo Zhao, David F Penson, Tatsuki Koyama, Ralph Conwill, Michael Goodman, Ann S Hamilton, Xiao-Cheng Wu and 9 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Prostate cancer and prostatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 1 country.

Jacob E TallmanDepartment of Urology, Vanderbilt University Medical Center, Nashville, TN, USA. jacob.tallman@vumc.org.ORCID http://orcid.org/0000-0002-9930-6493
Christopher J D WallisDepartment of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-5990-4026
Li-Ching HuangDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Zhiguo ZhaoDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
David F PensonDepartment of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-2580-2697
Tatsuki KoyamaDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Ralph ConwillOffice of Patient and Community Education, Patient Advocacy Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Michael GoodmanDepartment of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA.
Ann S HamiltonDepartment of Preventive Medicine, Keck School of Medicine at the University of Southern California, Los Angeles, CA, USA.
Xiao-Cheng WuDepartment of Epidemiology, Louisiana State University New Orleans School of Public Health, New Orleans, LA, USA.
Lisa E PaddockDepartment of Epidemiology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Antoinette StroupDepartment of Epidemiology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Matthew R CooperbergDepartment of Urology, University of California, San Francisco, CA, USA.
Mia HashibeDepartment of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
Brock B O'NeilDepartment of Urology, University of Utah Health, Salt Lake City, UT, USA.
Sherrie H KaplanDepartment of Medicine, University of California Irvine, Irvine, CA, USA.
Sheldon GreenfieldDepartment of Medicine, University of California Irvine, Irvine, CA, USA.
Daniel A BarocasDepartment of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.
Karen E HoffmanDepartment of Radiation Oncology, University of Texas M. D. Anderson Center, Houston, TX, USA.
Vanderbilt University Medical Center · USRutgers, The State University of New Jersey · USUniversity of California, Irvine · USUniversity of Utah · USEmory University · USLouisiana State University · USThe University of Texas MD Anderson Cancer Center · USUniversity of California, San Francisco · USUniversity of Southern California · US

Funding

Repurposing of a Long-Acting Parathyroid Hormone Analog for the Treatment of HypoparathyroidismZIATR000011 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI YANG, NA · 2015 to 2019
$8.2M
Comparative Effectiveness of Treatments for Localized Prostate CancerR01HS019356 · AHRQ · VANDERBILT UNIVERSITY · PI PENSON, DAVID F. · 2010 to 2010
$7.6M
Surgical Oncology Training GrantT32CA106183 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI James Richard Goldenring · 2004 to 2026
$6.0M
10-year Comparative Effectiveness and Harms of Treatments for Prostate CancerR01CA230352 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BAROCAS, DANIEL A · 2019 to 2023
$3.1M
Comparative Effectiveness of Modern Therapies for Localized Prostate CancerR01HS022640 · AHRQ · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PENSON, DAVID F. · 2013 to 2013
$1.8M
AHRQ HHS R01 HS019356AHRQ HHS R01 HS022640NCI NIH HHS R01 CA230352Patient-Centered Outcomes Research Institute (PCORI) CE-12-11-4667U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 5T32CA106183U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS) UL1TR000011
6 · The paper itself

Abstract

backgroundPrior studies have shown significant variability in the quality of prostate cancer care in the US with questionable associations between quality measures and patient reported outcomes. We evaluated the impact of compliance with nationally recognized radiation therapy (RT) quality measures on patient-reported health-related quality of life (HRQOL) outcomes in the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) cohort.

methodsCEASAR is a population-based, prospective cohort study of men with localized prostate cancer from which we identified 649 who received primary RT and completed HRQOL surveys for inclusion. Eight quality measures were identified based on national guidelines. We analyzed the impact of compliance with these measures on HRQOL assessed by the 26-item Expanded Prostate Index Composite at pre-specified intervals up to 5 years after treatment. Multivariable analysis was performed controlling for demographic and clinicopathologic features.

resultsAmong eligible participants, 566 (87%) patients received external beam radiation therapy and 83 (13%) received brachytherapy. Median age was 69 years (interquartile range: 64-73), 33% had low-, 43% intermediate-, and 23% high-risk disease. 28% received care non-compliant with at least one measure. In multivariable analyses, while some statistically significant associations were identified, there were no clinically significant associations between compliance with evaluated RT quality measures and patient reported urinary irritative, urinary incontinence, bowel, sexual or hormonal function.

conclusionsCompliance with RT quality measures was not meaningfully associated with patient-reported outcomes after prostate cancer treatment. Further work is needed to identify patient-centered quality measures of prostate cancer care.

Indexed as

BrachytherapyProstatic NeoplasmsUrinary IncontinenceAgedHumansMalePatient Reported Outcome MeasuresProspective StudiesQuality of Life

Identifiers

PMID35217831
PMCPMC11289781
OpenAlexW4214512828

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.